Variant · Expression
JAK2 Overexpression
CI-VAR-00003218Explore in graph →CIViC 3568
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29351986
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Hodgkin Lymphoma1 | ||||||||
| JAK2 Overexpression | (prognostic) | Prognostic | B | Supports Better Outcome | 2 | submitted | EID9776In a phase II study of JAK2 inhibitor ruxolitinib, patients with advanced relapsed or refractory Hodgkin lymphoma examined potential JAK2 amplification in 12 patients which found JAK1 amplification to… (full text at CIViC) PMID 29351986 · Van Den Neste et al., 2018 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available
No ClinVar interpretation attached to this variant.